Age-related Macular Degeneration (AMD) Drugs Market - Global Forecast to 2029

Table of Content

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 33
1.3 INCLUSIONS AND EXCLUSIONS 33
1.4 STUDY SCOPE 34
1.4.1 MARKETS COVERED 34
1.4.2 YEARS CONSIDERED 35
1.4.3 CURRENCY CONSIDERED 35
1.5 STAKEHOLDERS 35
1.6 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION DRUGS MARKET 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
2.1.1 SECONDARY DATA 38
2.1.2 PRIMARY DATA 38
2.2 MARKET SIZE ESTIMATION 40
2.2.1 BOTTOM-UP APPROACH 43
2.3 MARKET GROWTH FORECAST 44
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 46
2.5 RESEARCH ASSUMPTIONS 46
2.6 RESEARCH LIMITATIONS 47
2.7 RISK ANALYSIS 47
3 EXECUTIVE SUMMARY 48
4 PREMIUM INSIGHTS 53
4.1 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET OVERVIEW 53
4.2 NORTH AMERICAN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SHARE, BY APPROVAL TYPE AND COUNTRY, 2023 54
4.3 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF
AMD, 2024 VS. 2029 (USD MILLION) 54
4.4 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2023 55
4.5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
GEOGRAPHIC GROWTH OPPORTUNITIES 55
?
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
5.2.1 DRIVERS 57
5.2.1.1 Changing lifestyle and dietary habits 57
5.2.1.2 Steady development and approvals of drugs 58
5.2.1.3 Favorable reimbursement and insurance policies 59
5.2.2 RESTRAINTS 60
5.2.2.1 Off-label use of drugs 60
5.2.3 OPPORTUNITIES 60
5.2.3.1 Shifting focus on new drug modalities 60
5.2.3.2 Rapidly expanding market in developing countries 61
5.2.3.3 Need to address dry age-related macular degeneration and geographic atrophy 62
5.2.4 CHALLENGES 63
5.2.4.1 Non-adherence to treatments 63
5.3 TECHNOLOGY ANALYSIS 64
5.3.1 KEY TECHNOLOGIES 64
5.3.1.1 Hybridoma technology 64
5.3.1.2 Recombinant DNA technology 64
5.3.1.3 Antibody engineering 65
5.3.2 ADJACENT TECHNOLOGIES 65
5.3.2.1 Tissue engineering (scaffold technology) 65
5.3.2.2 Artificial intelligence 66
5.3.2.3 Optogenetic technology 66
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67
5.5 PRICING ANALYSIS 67
5.5.1 AVERAGE SELLING PRICING OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE) 68
5.5.2 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION 68
5.5.3 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER 69
5.6 VALUE CHAIN ANALYSIS 70
5.7 SUPPLY CHAIN ANALYSIS 72
5.8 ECOSYSTEM ANALYSIS 73
5.9 PATENT ANALYSIS 75
5.10 REGULATORY ANALYSIS 77
5.10.1 REGULATORY LANDSCAPE 77
5.10.1.1 US 78
5.10.1.2 Europe 79
5.10.1.3 Emerging economies 79
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
5.11 PORTER’S FIVE FORCES ANALYSIS 83
5.11.1 INTENSITY OF COMPETITIVE RIVALRY 84
5.11.2 BARGAINING POWER OF SUPPLIERS 85
5.11.3 BARGAINING POWER OF BUYERS 85
5.11.4 THREAT OF SUBSTITUTES 85
5.11.5 THREAT OF NEW ENTRANTS 85
5.12 KEY CONFERENCES AND EVENTS, 2024–2025 86
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 87
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 87
5.13.2 BUYING CRITERIA 87
5.14 INVESTMENT/FUNDING ACTIVITY 89
5.15 PIPELINE ANALYSIS 89
5.16 CASE STUDY ANALYSIS 92
5.16.1 IMPROVED EFFICACY OF RGX-314 FOR WET AGE-RELATED
MACULAR DEGENERATION TREATMENT 92
5.16.2 ENHANCED EFFICACY OF EYLEA HD FOR WET AGE-RELATED
MACULAR DEGENERATION TREATMENT 92
5.16.3 HIGHER EFFICACY AND SAFETY OF FARICIMAB FOR NEOVASCULAR
AGE-RELATED MACULAR DEGENERATION TREATMENT 92
5.17 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET 93
6 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY PRODUCT 95
6.1 INTRODUCTION 96
6.2 EYLEA & EYLEA HD 96
6.2.1 HIGHER PREFERENCE BY OPHTHALMOLOGISTS AND PATIENTS
TO SPEED UP GROWTH 96
6.3 LUCENTIS 100
6.3.1 PROVEN ABILITY TO IMPROVE VISUAL ACUITY AND RETINAL
THICKNESS TO FAVOR GROWTH 100
6.4 VABYSMO 104
6.4.1 FAVORABLE APPROVAL FROM GOVERNMENT AUTHORITIES
TO SUSTAIN GROWTH 104
6.5 SYFOVRE 107
6.5.1 INCREASING PREVALENCE OF ADVANCED DRY AGE-RELATED
MACULAR DEGENERATION TO BOOST MARKET 107
6.6 OTHER PRODUCTS 111
?
7 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY MOLECULE 114
7.1 INTRODUCTION 115
7.2 AFLIBERCEPT 115
7.2.1 HIGHER EFFICIENCY IN TREATING RETINAL DISORDERS
TO EXPEDITE GROWTH 115
7.3 FARICIMAB 119
7.3.1 FAVORABLE ADOPTION AND OUTCOMES OF RESEARCH
STUDIES TO AUGMENT GROWTH 119
7.4 RANIBIZUMAB 122
7.4.1 ENHANCED RESULTS COMPARED TO LASER TREATMENT TO DRIVE MARKET 122
7.5 PEGCETACOPLAN 126
7.5.1 HIGHER ADOPTION IN TREATING GEOGRAPHIC ATROPHY TO
CONTRIBUTE TO GROWTH 126
7.6 OTHER MOLECULES 129
8 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY APPROVAL TYPE 133
8.1 INTRODUCTION 134
8.2 BIOLOGICS 134
8.2.1 HIGHER CLINICAL VALIDATION AND REGULATORY ADVANTAGES
TO SUPPORT GROWTH 134
8.3 BIOSIMILARS 138
8.3.1 LOW DEVELOPMENT AND APPROVAL TO FAVOR MARKET GROWTH 138
9 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY TYPE OF AMD 142
9.1 INTRODUCTION 143
9.2 WET AMD 143
9.2.1 GROWING GERIATRIC POPULATION TO FACILITATE GROWTH 143
9.3 DRY AMD 147
9.3.1 INCREASED RESEARCH & DEVELOPMENT EFFORTS TO PROMOTE GROWTH 147
10 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET,
BY END USER 151
10.1 INTRODUCTION 152
10.2 HOSPITALS 152
10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO STIMULATE GROWTH 152
10.3 LONG-TERM CARE FACILITIES 156
10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET 156
10.4 SPECIALTY CENTERS 159
10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH 159
11 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION 163
11.1 INTRODUCTION 164
11.2 NORTH AMERICA 164
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 168
11.2.2 US 169
11.2.2.1 Rising investment in healthcare research & development
to propel market 169
11.2.3 CANADA 172
11.2.3.1 Favorable government initiatives to aid market growth 172
11.3 EUROPE 174
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 176
11.3.2 GERMANY 178
11.3.2.1 Rising focus on clinical research with public-private partnerships to augment growth 178
11.3.3 UK 181
11.3.3.1 Ongoing technological advancements to promote growth 181
11.3.4 FRANCE 183
11.3.4.1 Growing investments in funding healthcare and allied technology to foster growth 183
11.3.5 ITALY 186
11.3.5.1 Comprehensive treatment coverage and funding for new therapies to fuel market 186
11.3.6 SPAIN 189
11.3.6.1 Growing number of collaborative projects to favor market growth 189
11.3.7 NETHERLANDS 192
11.3.7.1 Increasing focus of clinical trials on biomarkers and hereditary conditions to drive market 192
11.3.8 REST OF EUROPE 194
11.4 ASIA PACIFIC 197
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 200
11.4.2 CHINA 201
11.4.2.1 Strategic drug approvals to support market growth 201
11.4.3 JAPAN 204
11.4.3.1 Advanced healthcare infrastructure to encourage growth 204
11.4.4 INDIA 206
11.4.4.1 Regulatory reforms and aging population to boost market 206
11.4.5 AUSTRALIA 209
11.4.5.1 Increasing disease incidence and evolving treatment options to facilitate growth 209
?
11.4.6 SOUTH KOREA 212
11.4.6.1 Supportive regulatory environment to boost market 212
11.4.7 REST OF ASIA PACIFIC 214
11.5 LATIN AMERICA 216
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 219
11.5.2 BRAZIL 220
11.5.2.1 Increasing rate of visual impairment to sustain growth 220
11.5.3 MEXICO 223
11.5.3.1 Growing research initiatives for alternative medicines and nano-based drug delivery system to speed up growth 223
11.5.4 REST OF LATIN AMERICA 225
11.6 MIDDLE EAST 227
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 230
11.6.2 GCC COUNTRIES 231
11.6.2.1 Saudi Arabia 233
11.6.2.1.1 Sustained health coverage and biosimilar drug approvals to propel market 233
11.6.2.2 UAE 235
11.6.2.2.1 Increasing focus on technological advancements, ongoing research, and government initiatives to support growth 235
11.6.2.3 Other GCC Countries 238
11.6.3 REST OF MIDDLE EAST 240
11.7 AFRICA 243
11.7.1 GROWING PREVALENCE OF PATIENT ADVOCACY GROUPS AND REGULATORY IMPROVEMENTS TO DRIVE MARKET 243
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 245
12 COMPETITIVE LANDSCAPE 247
12.1 OVERVIEW 247
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 247
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET 248
12.3 REVENUE ANALYSIS, 2021–2023 250
12.4 MARKET SHARE ANALYSIS, 2023 251
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 253
12.5.1 STARS 254
12.5.2 EMERGING LEADERS 254
12.5.3 PERVASIVE PLAYERS 254
12.5.4 PARTICIPANTS 254
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 256
12.5.5.1 Company footprint 256
12.5.5.2 Molecule footprint 257
12.5.5.3 Approval footprint 258
12.5.5.4 Type of AMD footprint 259
12.5.5.5 Region footprint 260
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 261
12.6.1 PROGRESSIVE COMPANIES 261
12.6.2 RESPONSIVE COMPANIES 261
12.6.3 DYNAMIC COMPANIES 261
12.6.4 STARTING BLOCKS 261
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 263
12.7 COMPANY VALUATION AND FINANCIAL METRICS 265
12.7.1 COMPANY VALUATION 265
12.7.2 FINANCIAL METRICS 266
12.8 BRAND/PRODUCT COMPARISON 267
12.9 COMPETITIVE SCENARIO 268
12.9.1 PRODUCT LAUNCHES & APPROVALS 268
12.9.2 DEALS 270
12.9.3 EXPANSIONS 271
13 COMPANY PROFILES 272
13.1 KEY PLAYERS 272
13.1.1 F. HOFFMANN-LA ROCHE LTD 272
13.1.1.1 Business overview 272
13.1.1.2 Products offered 273
13.1.1.3 Recent developments 274
13.1.1.3.1 Product launches & approvals 274
13.1.1.4 MnM view 275
13.1.1.4.1 Right to win 275
13.1.1.4.2 Strategic choices 275
13.1.1.4.3 Weaknesses and competitive threats 275
13.1.2 REGENERON PHARMACEUTICALS INC. 276
13.1.2.1 Business overview 276
13.1.2.2 Products offered 277
13.1.2.3 Recent developments 277
13.1.2.3.1 Product launches & approvals 277
13.1.2.4 MnM view 277
13.1.2.4.1 Right to win 277
13.1.2.4.2 Strategic choices 278
13.1.2.4.3 Weaknesses and competitive threats 278
13.1.3 NOVARTIS AG 279
13.1.3.1 Business overview 279
13.1.3.2 Products offered 281
13.1.3.3 Recent developments 281
13.1.3.3.1 Product launches & approvals 281
13.1.3.3.2 Deals 282
13.1.3.4 MnM view 282
13.1.3.4.1 Right to win 282
13.1.3.4.2 Strategic choices 282
13.1.3.4.3 Weaknesses and competitive threats 282
13.1.4 BAYER AG 283
13.1.4.1 Business overview 283
13.1.4.2 Products offered 284
13.1.4.3 Recent developments 285
13.1.4.3.1 Product launches & approvals 285
13.1.4.4 MnM view 285
13.1.4.4.1 Right to win 285
13.1.4.4.2 Strategic choices 285
13.1.4.4.3 Weaknesses and competitive threats 286
13.1.5 APELLIS PHARMACEUTICALS 287
13.1.5.1 Business overview 287
13.1.5.2 Products offered 287
13.1.5.3 Recent developments 288
13.1.5.3.1 Product launches & approvals 288
13.1.5.3.2 Deals 288
13.1.5.4 MnM view 289
13.1.5.4.1 Right to win 289
13.1.5.4.2 Strategic choices 289
13.1.5.4.2.1 Weaknesses and competitive threats 289
13.1.6 ASTELLAS PHARMA INC. 290
13.1.6.1 Business overview 290
13.1.6.2 Products offered 291
13.1.6.3 Recent developments 292
13.1.6.3.1 Product launches & approvals 292
13.1.6.3.2 Deals 292
13.1.7 STADA ARZNEIMITTEL AG 293
13.1.7.1 Business overview 293
13.1.7.2 Products offered 294
13.1.7.3 Recent developments 295
13.1.7.3.1 Product launches & approvals 295
13.1.7.3.2 Deals 296
13.1.8 BIOGEN 297
13.1.8.1 Business overview 297
13.1.8.2 Products offered 298
13.1.8.3 Recent developments 299
13.1.8.3.1 Product launches & approvals 299
?
13.1.9 FORMYCON AG 301
13.1.9.1 Business overview 301
13.1.9.2 Products offered 302
13.1.9.3 Recent developments 303
13.1.9.3.1 Product launches & approvals 303
13.1.9.3.2 Deals 304
13.1.10 COHERUS BIOSCIENCES 305
13.1.10.1 Business overview 305
13.1.10.2 Products offered 305
13.1.10.3 Recent developments 306
13.1.10.3.1 Products launches & approvals 306
13.1.10.3.2 Other developments 306
13.1.11 BIOCON 307
13.1.11.1 Business overview 307
13.1.11.2 Product offered 308
13.1.11.3 Recent developments 309
13.1.11.3.1 Product launches & approvals 309
13.1.11.3.2 Deals 309
13.1.12 OUTLOOK THERAPEUTICS, INC. 310
13.1.12.1 Business overview 310
13.1.12.2 Products offered 310
13.1.12.3 Recent developments 311
13.1.12.3.1 Product launches & approvals 311
13.1.12.3.2 Deals 311
13.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD. 312
13.1.13.1 Business overview 312
13.1.13.2 Products offered 313
13.1.13.3 Recent developments 314
13.1.13.3.1 Product launches & approvals 314
13.1.13.3.2 Deals 314
13.1.14 INTAS PHARMACEUTICALS LTD. 315
13.1.14.1 Business overview 315
13.1.14.2 Products offered 315
13.1.15 SANDOZ GROUP AG 316
13.1.15.1 Business overview 316
13.1.15.2 Products offered 317
13.1.15.3 Recent developments 318
13.1.15.3.1 Product launches & approvals 318
13.1.15.3.2 Deals 318
13.1.15.3.3 Expansions 318
?
13.1.16 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD. 319
13.1.16.1 Business overview 319
13.1.16.2 Products offered 319
13.2 OTHER PLAYERS 320
13.2.1 OCULAR THERAPEUTIX, INC. 320
13.2.2 OPTHEA LIMITED 321
13.2.3 KODIAK SCIENCES INC. 322
13.2.4 BIO-THERA 323
13.2.5 AMGEN INC. 323
13.2.6 ALVOTECH 324
13.2.7 STEALTH BIOTHERAPEUTICS INC. 325
13.2.8 ALTEOGEN INC. 326
13.2.9 OCUMENSION THERAPEUTICS 326
13.2.10 INNOVENT 327
13.2.11 SHANGHAI HENLIUS BIOTECH, INC. 327
14 APPENDIX 328
14.1 DISCUSSION GUIDE 328
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 332
14.3 CUSTOMIZATION OPTIONS 334
14.4 RELATED REPORTS 334
14.5 AUTHOR DETAILS 335

List of Figures

FIGURE 1 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SEGMENTATION 34
FIGURE 2 RESEARCH DESIGN 37
FIGURE 3 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
BREAKDOWN OF PRIMARY INTERVIEWS 39
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023 40
FIGURE 5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
REVENUE SHARE ANALYSIS, 2023 41
FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD: COMPANY REVENUE SHARE ANALYSIS, 2023 41
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 42
FIGURE 8 BOTTOM-UP APPROACH 43
FIGURE 9 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
CAGR PROJECTIONS, 2024–2029 44
FIGURE 10 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
GROWTH ANALYSIS OF MARKET DYNAMICS 45
FIGURE 11 DATA TRIANGULATION 46
FIGURE 12 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 48
FIGURE 13 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2024 VS. 2029 (USD MILLION) 49
FIGURE 14 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY TYPE OF AMD, 2024 VS. 2029 (USD MILLION) 49
FIGURE 15 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY TYPE OF APPROVAL, 2024 VS. 2029 (USD MILLION) 50
FIGURE 16 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 51
FIGURE 17 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY REGION, 2024–2029 52
FIGURE 18 GROWING GERIATRIC POPULATION AND CHANGING LIFESTYLES TO DRIVE MARKET 53
FIGURE 19 BIOLOGICS SEGMENT AND US DOMINATED NORTH AMERICAN MARKET IN 2023 54
FIGURE 20 WET AMD SEGMENT TO LEAD MARKET BY 2029 54
FIGURE 21 HOSPITALS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 55
FIGURE 22 NORTH AMERICA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 55
FIGURE 23 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
FIGURE 24 REVENUE SHIFT & NEW POCKETS FOR AGE-RELATED MACULAR
DEGENERATION THERAPY PROVIDERS 67
FIGURE 25 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION, 2021–2023 (USD) 69
FIGURE 26 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
VALUE CHAIN ANALYSIS 70
FIGURE 27 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
SUPPLY CHAIN ANALYSIS 72
FIGURE 28 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
ECOSYSTEM ANALYSIS 73
FIGURE 29 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
PATENT ANALYSIS, 2014–2024 76
FIGURE 30 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
PORTER’S FIVE FORCES ANALYSIS 84
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AGE-RELATED
MACULAR DEGENERATION (AMD) DRUGS 87
FIGURE 32 KEY BUYING CRITERIA, BY END USER 87
FIGURE 33 IMPACT OF ARTIFICIAL INTELLIGENCE ON AGE-RELATED MACULAR
DEGENERATION (AMD) DRUGS MARKET 93
FIGURE 34 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD)
DRUGS MARKET SNAPSHOT 165
FIGURE 35 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD)
DRUGS MARKET SNAPSHOT 197
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD MILLION) 250
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023 251
FIGURE 38 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 255
FIGURE 39 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
COMPANY FOOTPRINT 256
FIGURE 40 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 262
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 265
FIGURE 42 EV/EBITDA OF KEY VENDORS 266
FIGURE 43 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: BRAND/PRODUCT COMPARISON 267
FIGURE 44 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023) 273
FIGURE 45 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2023) 276
FIGURE 46 NOVARTIS AG: COMPANY SNAPSHOT (2023) 280
FIGURE 47 BAYER AG: COMPANY SNAPSHOT (2023) 284
FIGURE 48 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2023) 291
FIGURE 49 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT (2023) 294
FIGURE 50 BIOGEN: COMPANY SNAPSHOT (2023) 298
FIGURE 51 FORMYCON AG: COMPANY SNAPSHOT (2023) 302
FIGURE 52 BIOCON: COMPANY SNAPSHOT (2023) 308
FIGURE 53 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023) 313
FIGURE 54 SANDOZ GROUP AG: COMPANY SNAPSHOT (2023) 317

List of Tables

TABLE 1 INCLUSIONS AND EXCLUSIONS 33
TABLE 2 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
IMPACT ANALYSIS OF MARKET DYNAMICS 57
TABLE 3 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE), 2021–2023 (USD) 68
TABLE 4 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER, 2021–2023 (USD) 69
TABLE 5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 74
TABLE 6 PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 75
TABLE 7 INNOVATIONS AND PATENT REGISTRATIONS, 2019–2023 76
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 80
TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 81
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 81
TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 82
TABLE 12 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 83
TABLE 13 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
PORTER’S FIVE FORCES ANALYSIS 83
TABLE 14 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET:
KEY CONFERENCES AND EVENTS, 2024–2025 86
TABLE 15 BUYING CRITERIA FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS BY END USER 88
TABLE 16 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS IN
CLINICAL PIPELINE, PHASE 3 90
TABLE 17 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 96
TABLE 18 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2023–2029 (MILLION UNITS) 96
TABLE 19 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY REGION, 2022–2029 (USD MILLION) 97
TABLE 20 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 21 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 22 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022–2029 (USD MILLION) 99
TABLE 23 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022–2029 (USD MILLION) 99
TABLE 24 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY REGION, 2022–2029 (USD MILLION) 99
TABLE 25 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 26 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY REGION, 2022–2029 (USD MILLION) 101
TABLE 27 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 28 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 29 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 30 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022–2029 (USD MILLION) 103
TABLE 31 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY REGION, 2022–2029 (USD MILLION) 103
TABLE 32 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022–2029 (USD MILLION) 103
TABLE 33 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY REGION, 2022–2029 (USD MILLION) 104
TABLE 34 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 35 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 36 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 37 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 38 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY REGION, 2022–2029 (USD MILLION) 106
TABLE 39 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 40 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY REGION, 2022–2029 (USD MILLION) 108
TABLE 41 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 42 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 43 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 44 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 45 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY REGION, 2022–2029 (USD MILLION) 110
TABLE 46 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 47 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY REGION, 2022–2029 (USD MILLION) 111
TABLE 48 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 49 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 50 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 51 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 52 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY REGION, 2022–2029 (USD MILLION) 113
TABLE 53 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 54 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION) 115
TABLE 55 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2022–2029 (USD MILLION) 116
TABLE 56 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 57 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 58 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 59 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 60 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2022–2029 (USD MILLION) 118
TABLE 61 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 62 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY REGION, 2022–2029 (USD MILLION) 119
TABLE 63 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 64 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 65 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 66 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 67 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY REGION, 2022–2029 (USD MILLION) 121
TABLE 68 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022–2029 (USD MILLION) 122
TABLE 69 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2022–2029 (USD MILLION) 123
TABLE 70 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 71 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 72 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 73 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 74 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2022–2029 (USD MILLION) 125
TABLE 75 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 76 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY REGION, 2022–2029 (USD MILLION) 126
TABLE 77 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 78 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 79 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 80 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 81 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY REGION, 2022–2029 (USD MILLION) 128
TABLE 82 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 83 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2022–2029 (USD MILLION) 130
TABLE 84 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 85 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 86 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 87 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 88 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2022–2029 (USD MILLION) 132
TABLE 89 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 90 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION) 134
TABLE 91 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY REGION, 2022–2029 (USD MILLION) 135
TABLE 92 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 93 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 94 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 95 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 96 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY REGION, 2022–2029 (USD MILLION) 137
TABLE 97 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 98 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY REGION, 2022–2029 (USD MILLION) 139
TABLE 99 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 100 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 101 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 102 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 103 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY REGION, 2022–2029 (USD MILLION) 141
TABLE 104 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 105 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY TYPE OF AMD, 2022–2029 (USD MILLION) 143
TABLE 106 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY REGION, 2022–2029 (USD MILLION) 144
TABLE 107 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 108 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 109 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 110 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 111 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY REGION, 2022–2029 (USD MILLION) 146
TABLE 112 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 113 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY REGION, 2022–2029 (USD MILLION) 148
TABLE 114 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 115 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 116 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 117 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 118 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY REGION, 2022–2029 (USD MILLION) 150
TABLE 119 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 120 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION) 152
TABLE 121 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION) 153
TABLE 122 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 123 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 124 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 125 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 126 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION) 155
TABLE 127 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 128 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION) 156
TABLE 129 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 130 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 131 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 132 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 133 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION) 158
TABLE 134 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 135 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2022–2029 (USD MILLION) 160
TABLE 136 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 137 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 138 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 139 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 140 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2022–2029 (USD MILLION) 162
TABLE 141 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 142 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION) 164
TABLE 143 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 166
TABLE 144 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION) 166
TABLE 145 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION) 166
TABLE 146 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION) 167
TABLE 147 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION) 167
TABLE 148 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 167
TABLE 149 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN NORTH AMERICA 168
TABLE 150 US HEALTHCARE SPENDING, 2020–2022 (USD MILLION) 169
TABLE 151 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY PRODUCT, 2022–2029 (USD MILLION) 170
TABLE 152 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY MOLECULE, 2022–2029 (USD MILLION) 170
TABLE 153 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY APPROVAL TYPE, 2022–2029 (USD MILLION) 171
TABLE 154 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY TYPE OF AMD, 2022–2029 (USD MILLION) 171
TABLE 155 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY END USER, 2022–2029 (USD MILLION) 171
TABLE 156 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY PRODUCT, 2022–2029 (USD MILLION) 172
TABLE 157 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY MOLECULE, 2022–2029 (USD MILLION) 173
TABLE 158 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY APPROVAL TYPE, 2022–2029 (USD MILLION) 173
TABLE 159 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY TYPE OF AMD, 2022–2029 (USD MILLION) 173
TABLE 160 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY END USER, 2022–2029 (USD MILLION) 174
TABLE 161 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY PRODUCT, 2022–2029 (USD MILLION) 174
TABLE 162 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY MOLECULE, 2022–2029 (USD MILLION) 175
TABLE 163 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY APPROVAL TYPE, 2022–2029 (USD MILLION) 175
TABLE 164 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY TYPE OF AMD, 2022–2029 (USD MILLION) 175
TABLE 165 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY END USER, 2022–2029 (USD MILLION) 176
TABLE 166 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 167 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN EUROPE 177
TABLE 168 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY PRODUCT, 2022–2029 (USD MILLION) 179
TABLE 169 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY MOLECULE, 2022–2029 (USD MILLION) 179
TABLE 170 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY APPROVAL TYPE, 2022–2029 (USD MILLION) 180
TABLE 171 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY TYPE OF AMD, 2022–2029 (USD MILLION) 180
TABLE 172 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY END USER, 2022–2029 (USD MILLION) 180
TABLE 173 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY PRODUCT, 2022–2029 (USD MILLION) 181
TABLE 174 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY MOLECULE, 2022–2029 (USD MILLION) 182
TABLE 175 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY APPROVAL TYPE, 2022–2029 (USD MILLION) 182
TABLE 176 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY TYPE OF AMD, 2022–2029 (USD MILLION) 182
TABLE 177 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY END USER, 2022–2029 (USD MILLION) 183
TABLE 178 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY PRODUCT, 2022–2029 (USD MILLION) 184
TABLE 179 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY MOLECULE, 2022–2029 (USD MILLION) 184
TABLE 180 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY APPROVAL TYPE, 2022–2029 (USD MILLION) 185
TABLE 181 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY TYPE OF AMD, 2022–2029 (USD MILLION) 185
TABLE 182 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY END USER, 2022–2029 (USD MILLION) 185
TABLE 183 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY PRODUCT, 2022–2029 (USD MILLION) 187
TABLE 184 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY MOLECULE, 2022–2029 (USD MILLION) 187
TABLE 185 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY APPROVAL TYPE, 2022–2029 (USD MILLION) 188
TABLE 186 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION) 188
TABLE 187 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY END USER, 2022–2029 (USD MILLION) 188
TABLE 188 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 190
TABLE 189 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY MOLECULE, 2022–2029 (USD MILLION) 190
TABLE 190 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION) 191
TABLE 191 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION) 191
TABLE 192 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY END USER, 2022–2029 (USD MILLION) 191
TABLE 193 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 192
TABLE 194 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION) 193
TABLE 195 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION) 193
TABLE 196 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION) 193
TABLE 197 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION) 194
TABLE 198 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 194
TABLE 199 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022–2029 (USD MILLION) 195
TABLE 200 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022–2029 (USD MILLION) 195
TABLE 201 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION) 195
TABLE 202 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022–2029 (USD MILLION) 196
TABLE 203 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY PRODUCT, 2022–2029 (USD MILLION) 198
TABLE 204 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY MOLECULE, 2022–2029 (USD MILLION) 198
TABLE 205 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY APPROVAL TYPE, 2022–2029 (USD MILLION) 199
TABLE 206 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY TYPE OF AMD, 2022–2029 (USD MILLION) 199
TABLE 207 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY END USER, 2022–2029 (USD MILLION) 199
TABLE 208 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 209 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN ASIA PACIFIC 201
TABLE 210 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY PRODUCT, 2022–2029 (USD MILLION) 202
TABLE 211 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY MOLECULE, 2022–2029 (USD MILLION) 203
TABLE 212 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY APPROVAL TYPE, 2022–2029 (USD MILLION) 203
TABLE 213 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION) 203
TABLE 214 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY END USER, 2022–2029 (USD MILLION) 204
TABLE 215 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY PRODUCT, 2022–2029 (USD MILLION) 205
TABLE 216 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY MOLECULE, 2022–2029 (USD MILLION) 205
TABLE 217 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY APPROVAL TYPE, 2022–2029 (USD MILLION) 205
TABLE 218 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022–2029 (USD MILLION) 206
TABLE 219 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET BY END USER, 2022–2029 (U